Related Experiment Video

Updated: Jun 24, 2026

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
11:32

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry

Published on: September 28, 2016

Ion channels, transporters, and pumps as targets for heart failure therapy

Darshan Doshi1, Steven O Marx

  • 1Division of Cardiology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.

Journal of Cardiovascular Pharmacology
|April 15, 2009
PubMed

Insights

Heart failure treatments targeting ion channels, transporters, and pumps show promise for improving cardiac contractility and reducing arrhythmias. This review explores their therapeutic potential for managing heart failure.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) is a major cause of illness and death.
  • CHF involves heart enlargement, reduced contractility, and increased risk of arrhythmias and sudden cardiac death.
  • Ion channel dysfunction is a key factor in CHF-related contractility issues and arrhythmias.

Purpose of the Study:

  • To review the role of ion channels, transporters, and pumps in heart failure.
  • To explore the therapeutic potential of targeting these proteins for CHF treatment.
  • To focus on strategies for improving cardiac contractility and managing arrhythmias in heart failure.

Main Methods:

  • Literature review of studies on ion channels, transporters, and pumps in heart failure.
  • Analysis of existing and potential therapeutic targets.
  • Focus on mechanisms underlying reduced contractility and arrhythmias.

Main Results:

  • Ion channels, transporters, and pumps are critical in regulating cardiac function.
  • Dysfunction in these proteins contributes significantly to heart failure pathophysiology.
  • Targeting these elements offers potential therapeutic benefits for CHF.

Conclusions:

  • Ion channels, transporters, and pumps represent viable therapeutic targets for heart failure.
  • Modulating these proteins may improve cardiac contractility and reduce arrhythmia incidence.
  • Further research into these targets could lead to novel CHF treatments.

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...